In Phase I/II trial in HER2-positive sarcomas, including 16 osteosarcomas, one Ewing sarcoma, one primitive neuroectodermal tumor, and one desmoplastic small round cell tumor, HER2-CAR T cell therapy induced stable disease in four patients without significant toxicity (51). Here, ERBB2 is linked to primitive neuroectodermal tumor.